ADJUVANT TRIAL OUTCOMES

See recommendation from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) below.

Durable benefit for HER2+ EBC patients maintained1,2

Based on the primary analysis of iDFS (primary endpoint) and first interim analysis of OS (secondary endpoint) dual anti-HER2 adjuvant therapy with PERJETA + Herceptin® (trastuzumab) + chemotherapy vs placebo + Herceptin + chemotherapy demonstrated a reduction in the risk of recurrence and in the risk of death, respectively, in patients with HER2+ early breast cancer (EBC).*1,3

Limitations of data: All exploratory analyses are descriptive; therefore, no formal conclusions can be drawn.

  • Overall survival was an exploratory secondary endpoint with a final analysis scheduled to occur 10 years after the last patient completed targeted therapy. The data cutoff date was November 28, 2024. The median follow-up time was 135.6 months (11.3 years)2

*Recurrence was defined as an invasive disease event or death.3
†All analyses stratified by nodal status, protocol version, central hormone receptor status, and adjuvant chemotherapy regimen. Stratification factors are defined according to the randomization data for iDFS.1
‡The 3-year event-free rate was derived from Kaplan-Meier estimates.1
HER2=human epidermal growth factor receptor 2; iDFS=invasive disease-free survival; OS=overall survival.

NCCN Category 1 Preferred

The ONLY CATEGORY 1, PREFERRED adjuvant option for HER2-positive, node-positive breast cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend pertuzumab (PERJETA) + trastuzumab + chemo as a Category 1, Preferred option.*†4

The recommendation is based on the results from the adjuvant APHINITY trial in HER2-positive early breast cancer. See throughout for more details.


*If the cancer is also hormone receptor-positive, endocrine therapy should also be used.
†Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Preferred: Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
NCCN=National Comprehensive Cancer Network® (NCCN®).

Select Important Safety Information: Left Ventricular Dysfunction

  • Assess LVEF prior to initiation of PERJETA and at regular intervals during treatment to ensure that LVEF is within normal limits. If LVEF declines and has not improved, or has declined further at the subsequent assessment, discontinuation of PERJETA and trastuzumab should be strongly considered

Secondary endpoints1

Median follow-up: 45.4 months (primary analysis)

PERJETA + Herceptin + chemotherapy vs placebo + Herceptin + chemotherapy

  • iDFS including second primary nonbreast cancer: HR=0.83, 95% CI: 0.68-1.00§
    • 3-year event-free rate: 93.5% (95% CI: 92.5-94.5) vs 92.5% (95% CI: 91.4-93.6)
  • DFS: HR=0.82, 95% CI: 0.68-0.99§
    • 3-year event-free rate: 93.4% (95% CI: 92.4-94.4) vs 92.3% (95% CI: 91.2-93.4)
  • OS: HR=0.89, 95% CI: 0.66-1.21§
    • 3-year event-free rate: 97.7% (95% CI: 97.0-98.3) vs 97.7% (95% CI: 97.1-98.3)

§All analyses stratified by nodal status, protocol version, central hormone receptor status, and adjuvant chemotherapy regimen. Stratification factors are defined according to the randomization data for iDFS.1

The APHINITY trial evaluated adjuvant patients with a range of high-risk features1,5

Learn more about the APHINITY trial design

APHINITY exploratory analysis: iDFS by patient subgroup1

Exploratory analyses without adjusting for multiple comparisons; therefore, results are considered descriptive.

In the intent-to-cure EBC setting, give your node-positive patients PERJETA + Herceptin-based therapy—a standard of care1,2,6

The node-positive subgroup taking PERJETA + Herceptin included both hormone receptor-positive and hormone receptor-negative patients.1,2

There was an inability to show a reduction in risk of recurrence for the node-negative subgroup.1,2

Injection needle icon

Discover another treatment—a fixed-dose, subcutaneous injection that's given in minutes.

Learn more
APHINITY safety profile
  1. PERJETA Prescribing Information. Genentech, Inc. 2025.
  2. Loibl S, Piccart M, Clark E, et al. Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or PLA + T + CT) in patients (PTS) with early HER2-positive operable breast cancer in APHINITY: final analysis at 11.3 years’ median follow-up. Oral presentation at: ESMO Breast Cancer; 2025 May 14-17; Munich, Germany. Abstract LBA1.
  3. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122-131.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 17, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding the content, use, or application of these guidelines and disclaims any responsibility for their application or use in any way.
  5. Data on file. Genentech, Inc.
  6. Jackisch C, Cortazar P, Geyer CE, et al. Risk-based decision-making in the treatment of HER2-positive early breast cancer: recommendations based on the current state of knowledge. Cancer Treatment Rev. 2021;99:102229.

Important Safety Information & Uses

Indications:

PERJETA® (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for:

  • the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer (EBC)
  • the adjuvant treatment of adults with HER2-positive early breast cancer (EBC) at high risk of recurrence

PERJETA® (pertuzumab) is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Important Safety Information

BOXED WARNINGS: Left Ventricular Dysfunction and Embryo-Fetal Toxicity

  • PERJETA can cause subclinical and clinical cardiac failure manifesting as decreased left ventricular ejection fraction (LVEF) and congestive heart failure (CHF). Evaluate cardiac function prior to and during treatment. Discontinue PERJETA treatment for a confirmed clinically significant decrease in left ventricular function
  • Exposure to PERJETA can cause embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception
    • Verify the pregnancy status of females of reproductive potential prior to the initiation of PERJETA. Advise pregnant women and females of reproductive potential that exposure to PERJETA in combination with trastuzumab during pregnancy or within 7 months prior to conception can result in fetal harm, including embryo-fetal death or birth defects. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of PERJETA in combination with trastuzumab
    • There is a pregnancy pharmacovigilance program for PERJETA. If PERJETA is administered during pregnancy, or if a patient becomes pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with trastuzumab, healthcare providers and patients should immediately report PERJETA exposure to Genentech at 1-888-835-2555

Contraindications

PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients.

Warnings and Precautions

Left Ventricular Dysfunction

  • PERJETA can cause left ventricular dysfunction, including symptomatic heart failure
  • Assess LVEF prior to initiation of PERJETA and at regular intervals during treatment to ensure that LVEF is within normal limits. If the LVEF declines and has not improved, or has declined further at the subsequent assessment, consider permanent discontinuation of PERJETA and trastuzumab
  • In the PERJETA-treated patients with MBC in CLEOPATRA, left ventricular dysfunction occurred in 4% of patients and symptomatic left ventricular systolic dysfunction (LVSD) (congestive heart failure) occurred in 1% of patients. Patients who received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF or left ventricular dysfunction
  • In patients receiving PERJETA as a neoadjuvant treatment in combination with trastuzumab and docetaxel in NeoSphere, LVEF decline >10% and a drop to <50% occurred in 8% of patients and left ventricular dysfunction occurred in 3% of patients. LVEF recovered to ≥50% in all these patients
  • In patients receiving neoadjuvant PERJETA in TRYPHAENA, LVEF decline >10% and a drop to <50% occurred in 7% of patients treated with PERJETA plus trastuzumab and fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by PERJETA plus trastuzumab and docetaxel, 16% of patients treated with PERJETA plus trastuzumab and docetaxel following FEC, and 11% of patients treated with PERJETA in combination with docetaxel, carboplatin, and trastuzumab (TCH). Left ventricular dysfunction occurred in 6% of patients treated with PERJETA plus trastuzumab and FEC followed by PERJETA plus trastuzumab and docetaxel, 4% of patients treated with PERJETA plus trastuzumab and docetaxel following FEC, and 3% of patients treated with PERJETA in combination with TCH. Symptomatic LVSD occurred in 4% of patients treated with PERJETA plus trastuzumab and docetaxel following FEC, 1% of patients treated with PERJETA in combination with TCH, and none of the patients treated with PERJETA plus trastuzumab and FEC followed by PERJETA plus trastuzumab and docetaxel. LVEF recovered to ≥50% in all but 1 patient
  • In patients receiving neoadjuvant PERJETA in BERENICE, in the neoadjuvant period, LVEF decline ≥10% and a drop to <50% as measured by ECHO/MUGA assessment occurred in 7% of patients treated with PERJETA plus trastuzumab and paclitaxel following ddAC, and 2% of patients treated with PERJETA plus trastuzumab and docetaxel following FEC. Ejection fraction decreased (asymptomatic LVD) occurred in 7% of patients treated with PERJETA plus trastuzumab and paclitaxel following dose-dense doxorubicin and cyclophosphamide (ddAC) and 4% of the patients treated with PERJETA plus trastuzumab and docetaxel following FEC in the neoadjuvant period. Symptomatic LVSD (New York Heart Association [NYHA] Class III/IV Congestive Heart Failure) occurred in 2% of patients treated with PERJETA plus trastuzumab and paclitaxel following ddAC and none of the patients treated with PERJETA plus trastuzumab and docetaxel following FEC in the neoadjuvant period
  • In patients receiving adjuvant PERJETA in APHINITY, the incidence of symptomatic heart failure (NYHA Class III/IV) with a LVEF decline ≥10% and a drop to <50% was 0.6%. Of the patients who experienced symptomatic heart failure, 47% of PERJETA-treated patients had recovered (defined as 2 consecutive LVEF measurements above 50%) at the data cutoff. The majority of the events (86%) were reported in anthracycline-treated patients. Asymptomatic or mildly symptomatic (NYHA Class II) declines in LVEF ≥10% and a drop to <50% were reported in 3% of PERJETA-treated patients, of whom 80% recovered at the data cutoff
  • PERJETA has not been studied in patients with a pretreatment LVEF value of <50%, a prior history of CHF, decreases in LVEF to <50% during prior trastuzumab therapy, or conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment, or a cumulative prior anthracycline exposure to >360 mg/m2 of doxorubicin or its equivalent

Embryo-Fetal Toxicity

  • Based on its mechanism of action and findings in animal studies, PERJETA can cause fetal harm when administered to a pregnant woman. PERJETA is a HER2/neu receptor antagonist. Cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported with use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy

Infusion-Related Reactions

  • PERJETA can cause serious infusion reactions, including fatal events
  • In CLEOPATRA, on the first day, when only PERJETA was administered, infusion-related reactions occurred in 13% of patients and <1% were Grade 3 or 4. The most common infusion reactions (≥1%) were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity, and vomiting. During the second cycle when all drugs were administered on the same day, the most common infusion reactions in the PERJETA-treated group (≥1%) were fatigue, dysgeusia, hypersensitivity, myalgia, and vomiting
  • In APHINITY, when PERJETA was administered in combination with trastuzumab and chemotherapy on the same day, infusion-related reactions occurred in 21% of patients with <1% of patients experiencing Grade 3-4 events
  • Observe patients closely for 60 minutes after the first infusion and for 30 minutes after subsequent infusions of PERJETA. If a significant infusion-related reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies. Monitor patients carefully until complete resolution of signs and symptoms. Consider permanent discontinuation in patients with severe infusion reactions

Hypersensitivity Reactions/Anaphylaxis

  • PERJETA can cause hypersensitivity reactions, including anaphylaxis
  • In CLEOPATRA, the overall frequency of hypersensitivity/anaphylaxis reactions was 11% in PERJETA-treated patients, with Grade 3-4 hypersensitivity reactions and anaphylaxis occurring in 2% of patients
  • In NeoSphere, TRYPHAENA, BERENICE, and APHINITY, hypersensitivity/anaphylaxis events were consistent with those observed in CLEOPATRA. In APHINITY, the overall frequency of hypersensitivity/anaphylaxis was 5% in the PERJETA-treated group. The incidence was highest in the PERJETA plus TCH treated group (8%) with 1% Grade 3-4 events
  • Observe patients closely for hypersensitivity reactions. Severe hypersensitivity, including anaphylaxis and fatal events, have been observed in patients treated with PERJETA. Angioedema has been described in post-marketing reports. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use prior to administration of PERJETA

Most Common Adverse Reactions

Neoadjuvant Treatment of Breast Cancer

  • The most common adverse reactions (>30%) with PERJETA in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia
  • The most common adverse reactions (>30%) with PERJETA in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of FEC were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia
  • The most common adverse reactions (>30%) with PERJETA in combination with docetaxel, carboplatin, and trastuzumab (TCH) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia
  • The most common adverse reactions (>30%) with PERJETA in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddAC were nausea, diarrhea, alopecia, fatigue, constipation, peripheral neuropathy, and headache
  • The most common adverse reactions (>30%) with PERJETA in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of FEC were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia

Adjuvant Treatment of Breast Cancer

  • The most common adverse reactions (>30%) with PERJETA in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy, and vomiting

Treatment of Metastatic Breast Cancer

  • The most common adverse reactions (>30%) with PERJETA in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see the full Prescribing Information for additional Important Safety Information, including BOXED WARNINGS.